Phase 2 N=48 SH-DS01 on Fecal Metagenomic Stability
Irritable Bowel Syndrome
Primary: Safety and Tolerability of DS-01 Treatment vs Placebo — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
Breast Adenocarcinoma · Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 12; 5; 20 Participants
N/A N=264 Silicone Gel for Postsurgical Scars of the Eyelid
Scarring Due to Treatment
Primary: Post-operative Scarring - Erythema — 1.67; 1.70; 1.50; 1.65 score on a scale — p=0.48
N/A N=60 Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes
Tobacco Use
Primary: Combustible Cigarette Use — 3.79; 3.64 Number of cigarettes smoked per day
N/A N=12 Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
Type 1 Diabetes
Primary: Percentage of Time the Glucose Level is Above 10 mmol/l — 17.2; 16.2 percentage of time spent above range
Phase 1 N=1,999 Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty
Osteoarthritis
Primary: Rate of Periprosthetic Infection (PJI) After Elective Total Joint Arthroplasty. — 7; 0; 3; 2 Participants
Phase 2 N=53 ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Presence or Absence of a Dose Limiting Toxicity (DLT) of ALT-803 in Combination With Nivolumab — 3; 3; 6; 8 Participants
Phase 1 N=18 A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
Renal Impairment
Primary: Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma — 769; 1160; 1430 nM·hr
N/A N=144 Integrated Predictive Monitoring for Sepsis and Necrotizing Enterocolitis
Sepsis · Necrotising Enterocolitis Neonatal
Primary: Number of Participants With Sepsis or Necrotizing Enterocolitis — 20; 124 Participants
Phase 2 N=190 A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) — 22.5; 34.3 Percentage of participants
Phase 2 N=199 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Cutaneous Neurofibroma · Neurofibromatosis 1
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants
N/A N=62 Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease
Parkinson's Disease · Musculoskeletal Pain · Repetitive Transcranial Magnetic Stimulation
Primary: Change From Baseline Over 2 Months (Group by Time Interaction) in Modified KING'S PD Pain Scale Domain 1 — 12.41; 13.64; 9.96; 14.71 units on a scale
N/A N=23 Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy
Iron-deficiency · Pregnancy Anemia · Obesity
Primary: Recruitment Feasibility — 10 percentage eligible and enrolled
N/A N=384 Role of Membrane Sweeping on Initiation of Labor and Vaginal Birth in Previous Cesarean Section
Vaginal Birth After Cesarean Section
Primary: Number of Participants With Onset of Labor by 40 Weeks — 119; 90 participants
N/A N=154 Understanding the Cognition and Decision Making of Community Anesthesiologists
Neuromuscular Blockade
Primary: Accuracy on 9-item NMMR Knowledge Test — 43.8 Percent